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Abstract
In clinical practices the aim of adding antibiotics treatment was to improve the outcomes. The objective 
of this study was to assess whether adding intravenous ciprofloxacin could bear more benefit despite 
the cost of treatment than that of intravenous ceftriaxone for hospitalized pneumonia. This retrospective 
study devided patients with pneumonia into two groups; first, patients received intravenous ceftriaxone 
therapy only (CTX group), second, patients received combination of intravenous ceftriaxone plus 
ciprofloxacin (CTXCP group). There were 171 patients recruited, 106 patients received CTX treatment 
and 65 patients received CTXCP. The data were matched between groups by age, gender, level of payment 
and comorbidities. The total cost of treating hospitalized pneumonia with CTXCP was higher than CTX 
(p=0,000). Meanwhile, the length of stay (LOS) and length of stay antbiotic related (LOSAR) were shorter 
in CTX group than CTXCP (11,32 vs 13,15 days, p=0,14 and 9,26 vs 12,09 days, p=0,000). Moreover, the 
success rate and first line clinal failure avoided (CFA) in CTX  group were better than CTXCP  (81,13% vs 
66,15%, p=0,027  and 71,79% vs  44,62%, p=0,000). This research concluded that adding ciprofloxacin 
intravenous as empiric treatment of hospitalized pneumonia did not improve outcomes but significantly 
increased the cost of treatment.
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Abstrak
Salah satu tujuan penambahan terapi antibiotik dalam praktek klinis adalah untuk meningkatkan hasil 
terapi. Namun hal tersebut dapat meningkatkan biaya perawatan. Tujuan dari penelitian ini adalah 
untuk mengetahui apakah penambahan terapi antibiotik ciprofloksacin akan meningkatkan efektifitas 
meskipun menambah biaya dibandingkan dengan monoterapi ceftriakson pada pasien pneumonia rawat 
inap. Penelitian ini mengambil data pasien pneumonia secara retrospektif dan membaginya menjadi dua 
kelompok; pertama, kelompok monoterapi ceftriakson (CTX); kedua, kelompok kombinasi ciprofloksacin 
dan ceftriakson (CTXCP).  Sejumlah 171 pasien pneumonia yang memenuhi kriteria, 106 pasien masuk 
kelompok CTX dan 65 pasien masuk dalam kelompok CTXCP. Kedua kelompok memiliki karakteristik 
yang sama dari segi jenis kelamin, usia, jenis pembayaran, dan penyakit komorbiditas. Hasil analisis 
menunjukkan total biaya perawatan pada kelompok CTXCP lebih tinggi dari pada kelompok CTX (Rp. 
12.120.000 vs Rp. 9.020.000, p=0,000). Perbandingan efektifitas menunjukkan lama rawat inap (length 
of stay,LOS) dan lama pemberian antibiotik saat rawat inap (length of stay antibiotic related,LOSAR) 
kelompok CTX lebih pendek dibandingkan CTXCP (11,32 vs 13,15 hari, p=0,14 and 9,26 vs 12,09 
hari, p=0,000). Selain itu, tingkat keberhasilan terapi dan kegagalan antibiotik pertama (first line clinical 
failure avoided,CFA) juga lebih bagus pada kelompok CTX (81,13% vs 66,15%, p=0,027  dan 71,79% 
vs  44,62%, p=0,000). Dari penelitian ini dapat disimpulkan bahwa penambahan terapi ciprofloksacin 
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sebagai terapi empiris pada pasien pneumonia rawat inap membutuhkan biaya yang lebih tinggi 
namun menghasilkan efektifitas yang lebih rendah dibandingkan monoterapi ceftriakson.  
Kata kunci: pneumonia, ceftriakson, ciprofloksacin, biaya, efektivitas
INTRODUCTION
 Pneumonia is related with high morbidity 
and mortality in hospitalized patients especially 
in   low-to-middle income countries.1,2 Pneumonia 
is the third cause of death after cardiovascular 
diseases and tuberculosis in Indonesia. The 
empirical antibiotics used to treat hospitalized 
pneumonia are diverse. The identification of 
leading pathogens causing pneumonia is rarely 
done in clinical practice. Therefore, therapy is 
usually based on presumptive pathogens which 
frequently cause pneumonia in adult patients, 
clinical presentation of the patient, and the 
epidemiology of local pathogens.3 Adherence to 
antibiotic guidelines was the most cost-effective 
strategy for hospitalized patients who admitted to 
the ward.4 
 The first-line empirical treatment of 
pneumonia is still being debated. Antibiotic 
therapy is more challenging in hospitalized 
pnemonia. The recommendation of empiric 
antibiotic on hospitalized pneumonia were 
respiratory quinolone (such as gatifloxacin, 
gemifloxacin, levofloxacin, and moxifloxacin) 
or third generation of  cephalosporins (such as 
ceftriaxone and cefotaxime) combined with 
macrolides.5–7 Recent evidence suggests the 
superiority of combination therapy compared with 
monotherapy for subset populations, particularly 
patients with severe community acquired 
pneumonia (CAP), bacteremic pneumococcal 
CAP, or intubated CAP.7 The effectiveness of the 
combination therapy between fluoroquinolones 
and beta-lactams in hospitalized pneumonia 
are rarely evaluated in clinical-trials research.8 
Many studies had focused on the combination 
of an extended-spectrum cephalosporin plus a 
macrolide9. Fluoroquinolone usually used alone 
in moderate pneumonia, especially respiratory 
quinolone (e.g gatifloxacin, gemifloxacin, 
levofloxacin, and moxifloxacin). While, the 
combination of a beta-lactam (e.g cephalosporin 
and penicilline) with old fluoroquinolone (e.g. 
ciprofloxacin) was recommended for pneumonia 
caused by Pseudomonas.7 The effectiveness of 
adding ciprofloxacin as empiric treatment in 
hospitalized pneumonia remains unclear and can 
increase the cost of treatment. The objective of 
this study is to compare the cost and effectiveness 
of ceftriaxone iv monotherapy (CTX) and 
ceftriaxone iv plus ciprofloxacin iv (CTXCP) in 
hospitalized pneumonia patients.
MATERIAL AND METHODS 
 This research was a retrospective study. 
The clinical and characteristics data were derived 
from medical record of hospitalized pneumonia 
patients in the period of January- December 2012. 
The study was conducted in Kariadi Public Hospital 
in Semarang, Indonesia. Data were devided into 
two groups based on their empiric antibiotic 
treatments; first, patients received intravenous 
ceftriaxone therapy only (CTX group); second, 
patients received combination of intravenous 
ceftriaxone plus ciprofloxacin (CTXCP group). 
The characteristics data of patients includes 
demographic (age and gender), type of payments, 
accomodation type, comorbidity diseases, and 
discharge information. The two groups were 
matched by age, gender, type of payments, and 
co-morbidity disease. The cost of treatment was 
derived from payment records which include 
accomodation, laboratory service, medical service, 
drugs and medical devices, and total cost.
 The inclusions criteria of this study were 
patients diagnosed as pneumonia,  hospitalized 
more than three days, patients, received 
ceftriaxone i.v with or without combination of 
ciprofloxacin i.v, was older than 18 years. Patients 
with aspiration pneumonia, immunocompromize 
disease (e.g HIV or terminal cancer), with others 
infectious diseases were excluded from this study. 
The pneumonia diagnosis was stated in medical 
record based on physical assesment, culture of 
bacteria, and posteroanterior chest X-ray. BTA test 
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was assessed to differentiate between pneumonia 
and tuberculosis. 
 The outcome parameters of this study 
were LOS (length of stay), LOSAR (length of stay 
antibiotic related), CFA (first line clinical failure 
avoided) and success rate. LOS represented the 
total number of days in the hospital, from the 
day of admission to the day of discharge, while 
LOSAR was the total number of days patients 
treated with intravenous antibiotic during 
hospitalization. CFA (clinical failure avoided) was 
clinical failure that can be avoided because of the 
first antibiotic treatment. The failure of antibiotic 
treatment was defined if 1) the antibiotic treatment 
was changed or another intravenous antibiotic 
was added during hospitalization, 2) the antibiotic 
treatment were longer than fourteen days, 3) the 
patients was die. Success rate was defined as a 
sustained improvement or resolution of the signs 
and symptoms of pneumonia patients, such as no 
additional antimicrobial therapy was indicated, it 
was stated by clinician on the medical record, or 
the intravenous antibiotic was changed into oral 
route.
 Demographic data were presented as per-
centage. The mean value of LOS and LOSAR 
between two groups were compared using Mann-
Whitney Test. Kolmogorv Smirnov was used to 
check the data normality. The success rate and 
CFA were analyzed by Chi Square test. Statistical 
tests performed with 95% confidence level.
RESULT
Patient profile
 A total 171 patients admitted with 
pneumonia were included in this study. 106 
(61.99%) patients were grouped in CTX and  65 
patients were in CTXCP group (38.01%) (Table. 
1). The two goups were matched in age, gender, 
type of payment and co-morbidites (p>0.05). 
However, sepsis complications were more 
common in the group CTXCP than CTX group 
(33.83% vs 2.38%, p = 0.044). The room type of 
accomodation also differed between two groups 
(p>0,011). CTXCP group mostly treated in a 
higher class than the CTX group. 
 The study showed  that the patients were 
dominated by male (94.74% ) rather than women. 
The average age of patients with hospitalized 
pneumonia was 56 years old with the highest 
percentage of aged> 40 years (84.80%). Most 
of the patients were covered by health insurance 
(56.14%) for the payments and treated in the 
third class ward (73.68% ). The most common 
comorbid disease was cardiovascular disease 
(56.73%) (Table 1). 
Cost comparations
 Costs in this study was counted from direct 
medical costs only, while indirect costs were not 
included in the analysis. This study classified  the 
cost into; cost of antibiotics, cost of accommodation, 
cost of laboratory tests, cost of ward, cost of drugs 
and medical devices, and the total cost. The cost 
of antibiotics in this study included parenteral 
and oral antibiotics, for topical antibiotics were 
not included in the cost components. Addition 
or  replacement of antibiotics due to the failure 
of empirical therapy were also included in the 
cost components of antibiotics. Cost of clinical 
pathology and microbiology laboratory test in 
CTXCP group was significantly higher than CTX 
group (p <0.05). The study showed that the total 
cost of pneumonia treatment was lower in CTX 
group than CTXCP group. However, there was no 
significant differences in antibiotic cost between 
CTX group and CTXCP (Table 2). 
Effectiveness comparations
 The data showed the mean value of LOS 
in CTX group was shorter than CTXCP group 
(11.32 ± 3.69 vs 13.15 ± 4.49 days, p = 0.014). 
LOSAR was calculated from the length of intrave-
nous antibiotic therapy during the hospitalization. 
The mean value of LOSAR in CTXCP group lon-
ger than in the CTX group (12.09 ± 4.40 vs 9.26 
± 3.52, p = 0.000).The result showed the mean of 
LOSAR was shorter than the value of LOS (Table 
3). The results showed the proportion of CFA in 
CTXCP group lower than CTX group (44.62% vs 
71.70%),  as well as the success rate in CTX was 
higher than in CTXCP (Table 3).
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Characteristics
Total 
(n = 171)
CTX 
(n = 106)
CTXCP 
(n = 65) *P value
Gender 0.303
Female 9 (5.26) 4 (3.78) 5 (7.69)
Male 162(94.74) 102 (96.22) 60 (92.31)
Age (years, mean ± SD) 56.11±13.77 56.00±14.24 0.840
18-40  26 (15.20) 16 (15.09) 10 (15.38)
40-60  76 (44.440 46 (43.40) 30 (46.15)
60-80 64 (37.43) 42 (39.62) 22 (33.85)
>80 5 (2.92) 2 (1.89) 3 (4.62)
Type of payment 0.814
Askes 38 (22.22) 24 (22.64) 14 (21.54)
Jamkesda 24 (14.04) 13 (12.26) 11 (16.92)
Jamkesmas 96 (56.14) 60 (56.60) 36 (55.38)
Private 13 (7.60) 9 (8.49) 4 (6.15)
Room classification 0.011*
Class 1 19 (11.11) 8 (7.55) 11(16.92)
Class 2 26 (15.20) 22 (20.75) 4 (6.15)
Class 3 126 (73.68) 76 (71.70) 50 (76.92)
Co-morbidities
Cardiovascular 97 (56.73) 59 (55.66) 38 (58.46) 0.720
Diabetes mellitus 33 (19.30) 21 (19.81) 12 (18.46) 0.828
Renal impairment 25 (14.62) 13 (12.26) 12 (18.46) 0.266
Liver disease 16 (9.36) 9 (8.49) 7 (10.77) 0.619
Neoplasma 17 (9.94) 13 (12.26) 4 (6.15) 0.195
Other lung disease 42 (24.56) 25 (23.58) 17 (26.15) 0.705
Sepsis complication 25 (14.62) 3 (2.83) 22 (33.85) 0.044*
Table 1. Characteristic and Demographic Among Hospitalized Pneumonia
Description: if not otherwise stated, the data depicted in n (%) = number patients (percentage)
* p value obtained from chi square test for categorical and ordinal data types, and unpaired t test for numerical data, significant if the p value 
<0.05
DISCUSSION
 The study showed that the two groups had 
the same criterias except sepsis complication and 
class of treatment. Room classification affected 
the cost of accomodation and the choice of 
branded antibiotics, while complication of sepsis 
implicated the severity of pneumonia disease 
between groups. The patients were dominated 
by male rather than female. Male sex is an 
independent factor which significantly increases 
the risk of pneumonia. Men are more susceptible 
to pneumonia due to high risk of smoking, which 
is higher in male.10 Most of the patients were aged 
> 40 years old. Age is a risk factor for pneumonia, 
especially in very young age (<2 years) or very 
old age (> 65 years).11 Recently, prevalence of 
pneumonia disease in elderly increase while the 
elderly population is increasing. Pneumonia 
morbidity and mortality rates also increased in 
elderly patients, especially with co-morbidities.10
 Most of the patients were covered by 
insurance and treated in the third class ward. 
Most hospitalized pneumonia patients in this 
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hospital were belong to Jamkesda insurance from 
the government which guarantees care for third 
class only. Otherwise, patients with private health 
insurance mostly distributed in first and second 
class. Class treatments will affect the total cost of 
treatments. 
 Cardiovascular disease was the most 
frequent  comorbid diseases encountered in this 
study. Comorbid diseases that usually affect the 
outcome of pneumonia treatment are cancer, 
diabetes, chronic obstructive pulmonary disease 
(COPD), asthma, and cardiovascular.12 Chronic 
Heart Disease (CHD), liver disease, and cancer 
proven to be significantly increase the risk of 
pneumonia.10
 The study showed no significant differences 
in antibiotic cost between CTX and CTXCP 
group. The define-daily dose cost of intravenous 
ciprofloxacin in Indonesia was 9-10 times higher 
than ceftriaxone. Hospitalized pneumonia were 
admitted to change from intravenous to oral 
antibiotics if there were improvement of clinical 
condition and able to tolerate oral therapy.13 Cost 
of clinical pathology laboratory and clinical 
microbiology in CTXCP group was higher than 
CTX. It may caused by higher sepsis complications 
in CTXCP groups, thus required more monitoring 
and more routine laboratory inspection. After all, 
the total cost of pneumonia treatment was lower in 
CTX group than CTXCP groups (Table 2). 
 The data showed the mean value of 
LOS in CTX group was lower than CTXCP 
group. LOS of pneumonia is affected by some 
factors, which are intubation, emergence of 
abscess, bacterial pneumonia, pleural effusion, 
and chronic heart failure.12 In CTXCP group, 
there were more cardiovascular diseases than 
CTX (Table 1). LOSAR was calculated from the 
length of intravenous antibiotic therapy during 
the hospitalization. LOSAR is widely used as an 
outcome of antibiotic therapy because it is more 
specific than LOS.14,15 The result showed the mean 
of LOSAR is shorter than the value of LOS (Table 
3). 
 CFA is used as one of the outcome 
parameters of antibiotic therapy in pneumonia.16 
The results showed the proportion of CFA in 
CTXCP group lower than CTX group (Table 3). 
Some factors that lead the failure of therapy were 
the increase of  antibiotic resistance, children aged 
<2 years, elderly age> 65 years, patients receiving 
beta-lactam 3 months earlier, alcoholism, 
immunocomprimize patients due to disease or 
treatment.7
 From the results can be concluded that the 
addition of intravenous ciprofloxacin as empirical 
antibiotic therapy in hospitalized pneumonia did not 
shorten the LOS and LOSAR and neither increase 
success rate and CFA. Old fluoroquinolones, 
such as ciprofloxacin, has good penetration on 
the tissue, thus it is widely used in treatment 
of respiratory infections.17 As the resistance of 
ciprofloxacin increase, it should be avoided in less 
severe pneumonia, because its activities are less 
adequate against S. pneumoniae, and can lead to 
another fluoroquinolones resistance.18 Resistance 
of ciprofloxacin against S. pneumoniae are more 
prevalent, so the Infectious Disease Society 
of America (IDSA) recommends respiratory 
fluoroquinolone for the treatment of pneumonia.19 
Ciprofloxacin in elderly is recommended only for 
pneumonia caused by Pseudomonas aeruginosa 
with duration of therapy of 15 days 18. Using 
fluoroquinolone repeatedly in outpatient therapy 
also increases the resistance of pneumonia.7 The 
combination therapy between aminoglycoside 
and fluoroquinolone did not differ significantly 
in terms of mortality when compared with beta-
lactam monotherapy as empirical or definitive 
therapy in patients with infection P.aeroginosa.20 
CONCLUSION
 
 From the study, it can be concluded that 
adding intravenous ciprofloxacin as empiric 
treatment of hospitalized pneumonia did not 
improve outcomes but significantly increase the 
cost of treatment.
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Type of Payment
Total 
(x 1000 rupiah) 
% CTX
(x 1000 rupiah)
CTXCP
(x 1000 rupiah)
P 
value*
Accommodation and Consulting 1950.86±1702.62 21.6 1631.11±1204.09 2472.31±2208.20 0.004*
Laboratory
Diagnostic 251.43±322.33 288.54±383.03 190.96±176.47 0.702
Clinical Pathology 2036.16±2148.84 1626.29±1765.2 2704.57±2533.91 0.000*
Clinical Microbiology 398.94±377.49 315.60±229.14 498.36±507.70 0.000*
Anatomical Pathology 371.56±156.48 374.26±177.37 363.00±112.76 0.129
Radiodiagnostic 580.36±740.90 631.59±868.30 495.88±459.71 0.529
Total cost of laboratory 3103.38±2447.51 34.4 2695.47±2165.56 3768.59±2737.29 0.001*
 Medical Care
Services geriatrics 175.00±66.58 177.69±65.25 171.82±68.97 0.399
Cardiac care 1818.14±3277.68 1125.20±967.59 2900.86±5183.99 0.930
Hemodialysis 2460.00±439.08 1950.00±189.40 2587.50±663.90 0.048
medical action 748.26±1657.97 742.39±1923.5 757.45±1108.98 0.001*
medical rehabilitation 154.53±95.24 150.96±93.21 159.96±99.11 0.691
medical equipment 656.68±748,40 401.67±347.47 867.97±1099.60 0.000*
Services of medical devices 556.07±508.73 501.72±472.93 630.18±548.18 0.023*
Total cost of services 1995.77±4298.62 22.1 1534.8±2347.5 2717.02±6257.86 0.005*
Drugs and Medical Devices 1963.50±3219.14 21.8 1253.0±2120.8 3100.2±4222.6 0.000*
Antibiotic
ceftriaxone 56.93±25.44 53.76±22.14 62.11±29.46 0.049
ciprofloxacin 314.28±210.36 0 314.17±235.34 0.000*
other parenteral antibiotics 1024.36±667.49 709.15±477.34 1252.01±875.88 0.006*
oral antibiotics 4.88±3.38 5.74±3.66 3.79±2.94 0.679
Total cost of antibiotics 551.56±1401.79 6.1 231.72±950.93 1073.15±1813.91 0.000*
Total cost 9020.01±9050.14 100 7038.6±4977.7 12120±12672 0.000*
Description: Data expressed in mean ± Standard deviation, calculated the cost per patient per hospitalization
* p value obtained from unpaired t test if normally distributed data, and Mann Whitney test if data is not normally distributed. p value 
significant if <0.05.
Table 2. Comparation of Cost Theraphy Between Groups
Effectiveness CTX CTXCP P value
LOS (days) 11.32±3.69 13.15±4.49 0.014*
LOSAR (days) 9.26±3.52 12.09±4.40 0.000*
Success rate (n, %) 86 (81.13) 43 (66.15) 0.027*
CFA (n,%) 76 (71.70) 29 (44.62) 0.000*
*value p obtained from the chi-square test for categorical data and Mann Whitney test for numerical data. p value significant if <0.05.
Table 3. Comparation of Outcome Theraphy Between Groups
 Penambahan Ciprofloksacin Intravena terhadap Ceftriakson sebagai  ... (Afifah Machlaurin, Satibi, dan Nanang Munif  Yasin)
79
REFERENCE
1. Ramirez JA, Anzueto AR. Changing needs of 
community-acquired pneumonia. J. Antimicrob 
Chemother. 2011 ; 66 (Suppl 3):3-9. 
2. Zar HJ, Madhi SA, Aston SJ, Gordon SB. 
Pneumonia in low and middle income 
countries: progress and challenges. Thorax. 
2013 ;68(11):1052–6. 
3. Ambroggio L, Taylor JA, Tabb LP, 
Newschaffer CJ, Evans AA, Shah SS. 
Comparative Effectiveness of Empiric 
β-Lactam Monotherapy and β-Lactam–
Macrolide Combination Therapy in Children 
Hospitalized with Community-Acquired 
Pneumonia. J Pediatr. 2012 ;161(6):1097–
1103.. 
4. Egger ME, Myers JA, Arnold FW, Pass LA, 
Ramirez JA, Brock GN. Cost effectiveness of 
adherence to IDSA/ATS guidelines in elderly 
patients hospitalized for Community-Aquired 
Pneumonia. BMC Med Inform Decis Mak. 
2016;16:34. 
5. Bhavnani SM, Ambrose PG. Cost-
effectiveness of oral gemifloxacin versus 
intravenous ceftriaxone followed by oral 
cefuroxime with/without a macrolide for 
the treatment of hospitalized patients with 
community-acquired pneumonia. Diagn 
Microbiol Infect Dis. 2008 ;60(1):59–64. 
6. Lim WS, Baudouin SV, George RC, Hill AT, 
Jamieson C, Le Jeune I, et al. BTS guidelines 
for the management of community acquired 
pneumonia in adults: update 2009. Thorax. 
2009 ;64(Suppl 3):55. 
7. Mandell LA, Wunderink RG, Anzueto A, 
Bartlett JG, Campbell GD, Dean NC, et al. 
Infectious Diseases Society of America/
American Thoracic Society consensus 
guidelines on the management of community-
acquired pneumonia in adults. Clin Infect Dis 
Off Publ Infect Dis Soc Am. 2007 ;44 :27-72. 
8. Kolditz M, Halank M, Höffken G. 
Monotherapy versus Combination Therapy 
in Patients Hospitalized with Community-
Acquired Pneumonia. Treat Respir Med. 
2006;5(6):371–83. 
9. Vázquez EG, Mensa J, Martínez JA, Marcos 
MA, Puig J, Ortega M, et al. Lower mortality 
among patients with community-acquired 
pneumonia treated with a macrolide plus a 
beta-lactam agent versus a beta-lactam agent 
alone. Eur J Clin Microbiol Infect Dis. 2005 
;24(3):190–5. 
10. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-
Blanco T, Raga-Luria X, Gomez-Bertomeu 
F. Epidemiology of community-acquired 
pneumonia in older adults: A population-based 
study. Respir Med. 2009;103(2):309–16. 
11. DiPiro J, Talbert RL, Yee G, Matzke G, 
Wells B, Posey LM. Pharmacotherapy: A 
Pathophysiologic Approach, 8th Edition. New 
York : McGraw-Hill Medical; 2011. . 
12. Friedman H, Song X, Crespi S, Navaratnam 
P. Comparative Analysis of Length of Stay, 
Total Costs, and Treatment Success between 
Intravenous Moxifloxacin 400 mg and 
Levofloxacin 750 mg among Hospitalized 
Patients with Community-Acquired 
Pneumonia. Value Health. 2009 ;12(8):1135–
43. 
13. Watkins RR, Lemonovich TL. Diagnosis 
and management of community-acquired 
pneumonia in adults. Am Fam Physician. 2011 
;83(11):1299–306. 
14. 14.  de Klerk GJ, van Steijn JHM, Lobatto S, 
Jaspers CAJJ, van Veldhuizen WCJ, Hensing 
CAJ, et al. A randomised, multicentre study 
of ceftriaxone versus standard therapy in the 
treatment of lower respiratory tract infections. 
Int J Antimicrob Agents. 1999 ;12(2):121–7. 
15. Querol-Ribelles JM, Tenías JM, Querol-Borrás 
JM, Labrador T, Nieto A, González-Granda 
D, et al. Levofloxacin versus ceftriaxone plus 
clarithromycin in the treatment of adults with 
community-acquired pneumonia requiring 
hospitalization. Int J Antimicrob Agents. 2005 
25(1):75–83. 
16. Martin M, Moore L, Quilici S, Decramer 
M, Simoens S. A cost-effectiveness analysis 
of antimicrobial treatment of community-
acquired pneumonia taking into account 
resistance in Belgium. Curr Med Res Opin. 
2008 ;24(3):737–51. 
17. van Zanten ARH, Polderman KH, van 
Geijlswijk IM, van der Meer GYG, 
Buletin Penelitian Kesehatan, Vol. 45, No. 2, Juni  2017: 73 - 80
80
Schouten MA, Girbes ARJ. Ciprofloxacin 
pharmacokinetics in critically ill patients: A 
prospective cohort study. J Crit Care. 2008 
;23(3):422–30. 
18. Thiem U, Heppner H-J, Pientka L. Elderly 
patients with community-acquired pneumonia: 
optimal treatment strategies. Drugs Aging. 
2011.1;28(7):519–37. 
19. Frei CR, Labreche MJ, Attridge RT. 
Fluoroquinolones in community-acquired 
pneumonia: guide to selection and appropriate 
use. Drugs. 2011 ;71(6):757–70. 
20. Vardakas KZ, Tansarli GS, Bliziotis IA, 
Falagas ME. β-Lactam plus aminoglycoside or 
fluoroquinolone combination versus β-lactam 
monotherapy for Pseudomonas aeruginosa 
infections: A meta-analysis. Int J Antimicrob 
Agents. 2013 ;41(4):301–10. 
